Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study

BACKGROUND: Clinical outcomes of anti–programmed death‑(ligand) 1 (anti–PD-[L]1) therapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa+) remain unclear; recent studies have reported either comparable or poorer outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rezazadeh Kalebasty, Arash, Benjamin, David J., Loriot, Yohann, Papantoniou, Dimitrios, Siefker-Radtke, Arlene O., Necchi, Andrea, Naini, Vahid, Carcione, Jenna Cody, Santiago-Walker, Ademi, Triantos, Spyros, Burgess, Earle F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Bladder Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806713/
https://www.ncbi.nlm.nih.gov/pubmed/36601039
http://dx.doi.org/10.1016/j.euros.2022.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806713/
https://www.ncbi.nlm.nih.gov/pubmed/36601039
http://dx.doi.org/10.1016/j.euros.2022.11.001

Ejemplares similares